SCHEMBL752313

SCHEMBL752313

CC(C)(C)c1ccc(S(=O)(=O)N2CCN(C(=O)c3ccc(Cl)c(Cl)c3)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 1/20 0.65
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
HPGD P15428 2/20 0.53
HSD11B1 P28845 2/20 0.53
LMNA P02545 3/20 0.52
ALDH1A1 P00352 2/20 0.52
GAA P10253 1/20 0.52
HTT P42858 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ALOX15 P16050 1/20 0.51
POLB P06746 1/20 0.51
NPBWR1 P48145 1/20 0.51
MCHR1 Q99705 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL751828 0.89 ALDH1A1 (0.66) GPR183MEN1KMT2AHPGDHSD11B1
SCHEMBL753931 0.87 CNR2 (0.58) GPR183MEN1KMT2AHSD11B1LMNA
SCHEMBL752706 0.86 LMNA (0.68) MEN1KMT2AHPGDLMNAALDH1A1
SCHEMBL734913 0.86 CA12 (0.59) GPR183MEN1KMT2AHSD11B1LMNA
SCHEMBL751859 0.85 GPR183 (0.53) GPR183MEN1KMT2AHSD11B1LMNA
SCHEMBL734826 0.85 KMT2A (0.55) GPR183MEN1KMT2AHSD11B1LMNA
SCHEMBL751716 0.84 LMNA (0.72) MEN1KMT2AHPGDHSD11B1LMNA
SCHEMBL752323 0.84 LMNA (0.72) MEN1KMT2AHPGDHSD11B1LMNA
SCHEMBL753929 0.84 ATM (0.61) MEN1KMT2AHPGDLMNAALDH1A1
SCHEMBL735124 0.83 LMNA (0.66) MEN1KMT2AHPGDHSD11B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170234881-A1 METHODS OF DIAGNOSING AND TREATING CANCER INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2017-08-17 US disclosed
US-20170234881-A1 METHODS OF DIAGNOSING AND TREATING CANCER INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2017-08-17 US disclosed
US-8138190-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2012-03-20 US disclosed
US-8138190-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2012-03-20 US disclosed
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AMGEN INC. 2009-07-09 US disclosed
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES AMGEN INC. 2009-07-09 US disclosed
US-7524848-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2009-04-28 US disclosed
US-7524848-B2 Diaza heterocyclic amide compounds and their uses AMGEN INC. (US) 2009-04-28 US disclosed
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses AMGEN INC. 2007-10-25 US disclosed
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses AMGEN INC. 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176768-A1 DIAZA HETEROCYCLIC AMIDE COMPOUNDS AND THEIR USES GPR119, GLP1R, INSR GPR183 2348/4885MEN1 989/4885KMT2A 531/4885
US-20070249626-A1 Diaza heterocyclic amide compounds and their uses GPR119, GLP1R, INSR GPR183 2348/4885MEN1 989/4885KMT2A 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.